![Nathan Jorgensen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nathan Jorgensen
Plus aucun poste en cours
Fortune : 585 980 $ au 31/05/2026
Profil
Nathan Dean Jorgensen is currently Director at Momentum Therapeutics.
Formerly, Director at OncoResponse, Inc., Chief Financial Officer at Voyager Therapeutics, Inc. from 2024 to 2026, Associate Research Analyst at Stifel, Nicolaus & Co., Inc. from 2012 to 2013, Senior Research Analyst at Calamos Advisors LLC, and Chief Financial Officer at Vor Biopharma, Inc. from 2020 to 2024.
Education includes an MBA from Cornell University in 2010, a doctorate from the University of Minnesota in 2007, and an undergraduate degree from St. John's University in 1999.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 24/02/2026 | 151 416 ( 0,25% ) | 585 980 $ | 31/05/2026 |
Postes actifs de Nathan Jorgensen
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Nathan Jorgensen
| Sociétés | Poste | Fin |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Directeur Financier/CFO | 08/05/2026 |
| VOR BIOPHARMA INC. | Directeur Financier/CFO | 21/06/2024 |
Stifel, Nicolaus & Co., Inc.
 Stifel, Nicolaus & Co., Inc. Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01/10/2013 |
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology Discovers cancer immunotherapies by interrogating the human immune system | Directeur/Membre du Conseil | - |
Calamos Advisors LLC
 Calamos Advisors LLC Investment ManagersFinance Calamos Advisors utilizes top-down insights with rigorous bottom-up fundamental research. They employ an active, high-conviction investment approach to building portfolios. A collaborative team-managed approach allows them to fully evaluate all elements of an investment idea. Top-down perspective, proprietary fundamental research and risk management drive the portfolio construction process across all strategies. | Analyst-Equity | - |
Formation de Nathan Jorgensen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
96
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Stifel, Nicolaus & Co., Inc.
Stifel, Nicolaus & Co., Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Calamos Advisors LLC
Calamos Advisors LLC Investment ManagersFinance Calamos Advisors utilizes top-down insights with rigorous bottom-up fundamental research. They employ an active, high-conviction investment approach to building portfolios. A collaborative team-managed approach allows them to fully evaluate all elements of an investment idea. Top-down perspective, proprietary fundamental research and risk management drive the portfolio construction process across all strategies. | Finance |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. John's University
 St. John's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Voyager Therapeutics, Inc.
 Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology Discovers cancer immunotherapies by interrogating the human immune system | Health Technology |
Vor Biopharma, Inc.
 Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
Choisissez Zonebourse 
